真实世界类风湿关节炎缓解期停用生物制剂DMARD的结局与风险因素
基于瑞士SCQM注册队列,318例DAS28-ESR缓解的RA患者停用b/tsDMARD后随访,76%在中位0.9年内失去缓解。女性、病程>4年及基线未达CDAI缓解标准者失去缓解更快,而持续使用csDMARD与更长的无b/tsDMARD缓解相关。
要点
- 真实世界中多数RA缓解期停用b/tsDMARD患者在1年内失去缓解。
- 女性、病程>4年及未达CDAI缓解标准是失去缓解的危险因素。
- 停用b/tsDMARD期间持续使用csDMARD与维持缓解相关。
核心结论
- 真实世界RA缓解期停用b/tsDMARD后多数患者在1年内失去缓解,严格缓解标准和csDMARD治疗与维持无药缓解相关。
研究设计与样本
- 基于瑞士临床质量管理(SCQM)注册的队列研究,纳入1997至2017年间DAS28-ESR缓解后停用bDMARD/tsDMARD的RA患者318例,采用Kaplan-Meier法和Cox回归分析。
主要发现
- 318例患者中241例(76%)在中位0.9年(95%CI:0.7,1.0)后失去缓解。
- 女性、病程>4年及基线未达CDAI缓解标准者失去缓解的时间更短。
- 停用b/tsDMARD期间使用csDMARD者缓解维持更久(HR 0.8,P=0.05,95%CI:0.6,1.0)。
关键数值与推荐
- 缓解定义为DAS28-ESR≤2.6,失去缓解定义为DAS28-ESR>2.6或重启bDMARD/tsDMARD。
临床怎么用
- 对达到缓解的RA患者考虑停用b/tsDMARD时,应评估是否满足更严格的CDAI缓解标准,并考虑继续联用csDMARD以降低复发风险。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Data from randomized controlled trials have shown the feasibility of discontinuation of bDMARD therapy in patients with RA that have reached remission. Criteria for selecting patients that are likely to remain in remission are still incompletely defined. We aimed to identify predictors of successful discontinuation of bDMARD therapy in the Swiss Clinical Quality Management (SCQM) registry, a real-world cohort of RA patients. METHODS: RA patients in DAS28-ESR remission who stopped bDMARD/tsDMARD treatment were included. Loss of remission was defined as a DAS28-ESR > 2.6 or restart of a bDMARD/tsDMARD. Time to loss of remission was the main outcome. Kaplan-Meier methods were applied and Cox regression was used for multivariable analyses adjusting for confounding factors. Missing data were imputed using multiple imputation. RESULTS: A total of 318 patients in a bDMARD/tsDMARD-free remission were followed between 1997 and 2017. In total, 241 patients (76%) lost remission after a median time of 0.9 years (95% CI: 0.7, 1.0). The time to loss of remission was shorter in women, in patients with a longer disease duration >4yrs and in patients who did not meet clinical disease activity index (CDAI) remission criteria at baseline. Remission was longer in patients with csDMARD therapy during b/tsDMARD free remission [hazard ratio (HR) 0.8, P =0.05, 95% CI: 0.6, 1.0]. CONCLUSION: In a real-world patient population, the majority of patients who discontinued b/tsDMARD treatment lost remission within <1 year. Our study confirms that fulfilment of more rigorous remission criteria and csDMARD treatment increases the chance of maintaining b/tsDMARD-free remission.
引用
- Arnold S, Jaeger VK, Scherer A, et al. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. Rheumatology (Oxford). 2021. PMID: 33848332. doi:10.1093/rheumatology/keab343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。